Why LexinFintech Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Cullinan Therapeutics (NASDAQ:CGEM), Ambow Education Holding (AMEX:AMBO)

LexinFintech (LX) reported a 4.3% decline in loan origination to RMB55.43B and a 49.7% drop in net income to RMB101M. The company expects a Q3 2026 net loss due to revenue contraction, higher credit costs, and severance expenses. Risk indicators worsened, with delinquency ratios rising. LX adjusted its dividend policy to annual distributions, delaying shareholder returns. The company is diversifying and cutting costs amid industry funding tightening.

LexinFintech reported Q2 revenue of CNY1.3B, down 21.1% sequentially, with credit business revenue falling 32.5%. The company has CNY2.5B in cash and expects a net loss in Q3 due to declining revenue, rising credit costs, and restructuring expenses. Lexin is diversifying into fintech and e-commerce services, with these segments contributing 45% of loan volume. The company tightened underwriting standards amid worsening risk metrics and changed its dividend policy to annual distributions to prese

LexinFintech Holdings Ltd. (LX) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 LexinFintech Holdings Ltd. Reports Second Quarter 2026 Unaudited Financial Results SHENZHEN, China, August 31, 2026 (GLOBE NEWSWIRE) -- LexinFintech Holdings Ltd. (“Lexin” or the “Company”) (NASDAQ: LX), a leading technology-empowered personal financial service enabl

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.